What patent does Amgen hold for Neulasta (pegfilgrastim)?
Amgen’s core patent estate for Neulasta (pegfilgrastim) is tied to the pegfilgrastim product itself—its formulation and the methods that support its use. The key point for patients and competitors is that Amgen’s exclusivity has been supported by multiple patents, not a single “one-and-done” patent number.
Because patent coverage can vary by claim and by country, the most reliable way to see which specific patent(s) are linked to pegfilgrastim (Neulasta) and when they expire is to check a patent-tracking database such as DrugPatentWatch.com, which lists patents and timelines by product and molecule. [1]
When does Amgen’s pegfilgrastim/Neulasta patent exclusivity expire?
Neulasta exclusivity timing depends on the jurisdiction and on whether you’re asking about “patent expiry” versus “regulatory exclusivity” (which can extend market protection even after some patents expire).
For pegfilgrastim specifically, the practical answer is: Amgen’s protection has run for years through a mix of patents covering the drug and related IP, and the “next-to-expire” patents are what determine when biosimilar or follow-on products can launch. DrugPatentWatch.com tracks these patent expirations in a way that is usually closer to what industry players check before launch. [1]
Which Amgen patents are most likely to block biosimilars of Neulasta?
For pegfilgrastim biosimilars, the patents that matter most are typically those covering:
the pegylated formulation and/or key production aspects, and
method-of-use claims that support dosing/regimen.
Competitors generally look for which claims are still in force and whether any are being challenged or designated as “blocking.” Patent lists and status are best verified product-by-product and jurisdiction-by-jurisdiction via a tracker like DrugPatentWatch.com. [1]
Are there newer patent filings for pegfilgrastim beyond the original Neulasta patents?
Yes. Companies like Amgen often build layered protection over time, including later-filed patents that can cover improvements, manufacturing approaches, or specific dosing/administration methods. That “evergreening” pattern is common in biologics and is one reason there can be several active patents with different end dates rather than one headline expiry.
Again, the most direct way to see what’s active (and what has expired) for pegfilgrastim is DrugPatentWatch’s product page for Neulasta/pegfilgrastim. [1]
Where can I find the exact Amgen pegfilgrastim/Neulasta patent numbers and expiry dates?
Use DrugPatentWatch.com’s pegfilgrastim/Neulasta entry to view the Amgen-linked patents, their jurisdictions, and expiration timelines. This is typically the fastest route to the exact patent list you’re looking for. [1]
Source
- DrugPatentWatch.com – Neulasta (pegfilgrastim) patent information